CA3246603A1 - COMPOSITIONS AND METHODS INTENDED FOR THE TREATMENT OF SOLID CANCER - Google Patents

COMPOSITIONS AND METHODS INTENDED FOR THE TREATMENT OF SOLID CANCER

Info

Publication number
CA3246603A1
CA3246603A1 CA3246603A CA3246603A CA3246603A1 CA 3246603 A1 CA3246603 A1 CA 3246603A1 CA 3246603 A CA3246603 A CA 3246603A CA 3246603 A CA3246603 A CA 3246603A CA 3246603 A1 CA3246603 A1 CA 3246603A1
Authority
CA
Canada
Prior art keywords
cancer
composition
bladder
glycine
myeloperoxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246603A
Other languages
English (en)
French (fr)
Inventor
Robert C. Allen
Jackson T. STEPHENS JR
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of CA3246603A1 publication Critical patent/CA3246603A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3246603A 2022-04-13 2023-04-12 COMPOSITIONS AND METHODS INTENDED FOR THE TREATMENT OF SOLID CANCER Pending CA3246603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330553P 2022-04-13 2022-04-13
US63/330,553 2022-04-13
PCT/US2023/018289 WO2023200842A1 (en) 2022-04-13 2023-04-12 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
CA3246603A1 true CA3246603A1 (en) 2023-10-19

Family

ID=88330172

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246603A Pending CA3246603A1 (en) 2022-04-13 2023-04-12 COMPOSITIONS AND METHODS INTENDED FOR THE TREATMENT OF SOLID CANCER

Country Status (10)

Country Link
US (1) US20250332226A1 (https=)
EP (1) EP4507793A1 (https=)
JP (1) JP2025512366A (https=)
KR (1) KR20250004257A (https=)
CN (1) CN119677528A (https=)
AU (1) AU2023252830A1 (https=)
CA (1) CA3246603A1 (https=)
IL (1) IL316053A (https=)
MX (1) MX2024012316A (https=)
WO (1) WO2023200842A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
CA3196357A1 (en) * 2020-11-11 2022-05-19 Robert C. Allen Compositions and methods for treating solid cancer

Also Published As

Publication number Publication date
EP4507793A1 (en) 2025-02-19
AU2023252830A1 (en) 2024-10-10
IL316053A (en) 2024-11-01
WO2023200842A1 (en) 2023-10-19
CN119677528A (zh) 2025-03-21
KR20250004257A (ko) 2025-01-07
MX2024012316A (es) 2024-11-08
US20250332226A1 (en) 2025-10-30
JP2025512366A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
US8617542B2 (en) DispersinB™, 5-fluorouracil, deoxyribonuclease I and proteinase K-based antibiofilm compositions and uses thereof
RU2529799C2 (ru) Композиции для усиления антибактериальной активности миелопероксидазы и способы их применения
EP1965763B1 (en) Stable enzymatic preparations and methods of use thereof
US8821862B2 (en) Soluble β-N-acetylglucosaminidase based antibiofilm compositions and uses thereof
AU2012281172B2 (en) Eosinophil peroxidase compositions and methods of their use
US20100111920A1 (en) Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases
US20230398190A1 (en) Compositions and methods for treating solid cancer
US20250332226A1 (en) Compositions and methods for treating solid cancer
JPH10509463A (ja) 炎症反応に起因する哺乳類の疾病の治療方法およびその組成物
JP2025539810A (ja) 改良された増強剤を含有するペルオキシダーゼ組成物
HK40098212A (zh) 用於治疗实体癌的组合物和方法
CN100428955C (zh) 辐射损伤防护剂组合物
JPH03204818A (ja) ヒトａｄｆを含有する医薬組成物
Bennett Defining a role for Xanthine oxidoreductase in promoting the healing of chronic ulcers
CA2525672A1 (en) Use of peroxovanadium compounds as tumour cell growth suppressor
WO2017079802A1 (en) Proenzyme composition
AU2013204669A1 (en) Methods and Compositions for the Treatment of Vaginal Diseases Employing Peroxide-Producing Enzymes and Peroxidases

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240924

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240924

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240924

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260331